As the programme develops we will be providing delegates with profiles of the speakers they will have the opportunity to see during the conference.
Please visit the site frequently for updates.
Margaret Stanley is Emeritus Professor of Epithelial Biology in the University of Cambridge and Honorary Fellow of Christs College, Cambridge. She attended the Universities of London, Bristol and Adelaide, she is a Fellow of the Academy of Medical Sciences and Honorary Fellow of the UK Royal College of Obstetricians and Gynaecologists. She has a lifetime award for contribution to research on cervical cancer and cervical precancers from the American Society for Colposcopy and Cytopathology (ASCCP) and a lifetime award for achievement from the International Papillomavirus Society. She was a member of the Spongiform Encephalopathies Advisory Committee that advised the UK government on prion diseases (mad cow disease) from 2004-2010. In 2004 she was awarded the OBE for services to Virology.
Her research has focussed on how the body defends itself against infections with HPV, how to develop vaccines that prevent HPV infection as well as those that might treat HPV infection. She is a consultant for the companies that market HPV vaccines, MSD, and GSK and for small biotech companies developing therapeutic vaccines. She acts as the invited HPV expert for the HPV subcommittee of the Joint Committee on Vaccines and Immunisation in the UK.
Prifessor Paul Davis co-founded Mologic in 2003. It has grown to 60FTEs and was recently funded by the Bill and Melinda Gates Foundation to set up the “Centre for Advanced Rapid Diagnostics”. In the 1980s he was one of the Unilever team which created the home pregnancy test (Clearblue), for which he invented much of the underlying patented technology. His current main focus is advanced PoC tests for host biomarkers of infection and inflammation.
Honorary professor appointments:-
• Department of Chemistry, University of Warwick
• Department of Biosciences, University of Kent
• University of Cardiff Medical School
Also Principal Visiting Staff Member, Biochemical Engineering, UCL
Derek Brown has worked for many years on aspects of antimicrobial susceptibility testing, antimicrobial action, and mechanisms of resistance. Most of his career was centered in Cambridge working for Public Health England (and its previous guises). He has been on the BSAC Antimicrobial Susceptibility Testing and Resistance Surveillance Standing Committees since their formation and has been actively involved in the UK NEQAS scheme for external quality assessment of antimicrobial susceptibility testing since the 1970s. He was Scientific Secretary of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) from its inception in 1979 until he recently retired.
Prof Martin Llewelyn is an Infectious Diseases consultant and clinical academic based in Brighton. His research and clinical practice focus on healthcare and antibiotic resistant infection. Major themes of his research are application of microbial whole-genome sequencing to the study of transmission and pathogenesis of S. aureus infection, evaluation of infection biomarkers and reducing antibiotic overuse in hospitals through optimization of treatment strategies.
Dr Sanjay Patel is a paediatric infectious diseases and immunology consultant working at Southampton Children’s Hospital, England. He trained at Cambridge University medical school before completing his paediatric training in London followed by his higher specialist training in paediatric infectious diseases and immunology at St Mary’s Hospital London, Great Ormond Street Hospital London and Newcastle Children’s Hospital. He has also worked within the field of paediatric HIV and TB in Pietermaritzburg, South Africa.
His specific areas of interest are OPAT and antibiotic stewardship. In 2012, he introduced the first paediatric outpatient parenteral antibiotic therapy (p-OPAT) service in the UK. He chaired the joint BSAC / British Paediatric Allergy, Immunology and Infectious Diseases Group p-OPAT national working group tasked to develop good practice guidelines for the introduction and delivery of p-OPAT services in the UK, which were published in October 2014. He was a member of the NICE antibiotic stewardship guideline development group which published guidelines in 2015. He is on the BSAC OPAT standing committee and sits on BSAC council. He is co-lead for the module on antimicrobial stewardship for the ESPID on-line antibiotic management course and runs infectious diseases courses at Imperial College and in Iceland.
Professor Alex van Belkum worked on microbial epidemiology, molecular and culture-based diagnostics and antimicrobial resistance testing over the past 15 years. He is director of microbiology research at bioMerieux, a diagnostics company based in the South of France. He is the editor-in-chief of European Journal of Clinical Microbiology and Infectious Diseases. He is the author of more than 500 PubMed-cited papers, has an H index of about 85 and an overall number of more than 30,000 citations. He has worked at the University of Leiden and Rotterdam, both in The Netherlands. He moved to industry 7 years ago.
Dr Matthew Snape is a consultant in General Paediatrics and Vaccinology at the Oxford University Hospitals NHS trust, a Jenner Investigator and an Honorary Senior Clinical Lecturer at the University of Oxford. Dr Snape trained at the Royal Children's Hospital, Melbourne, and at St Mary's Hospital, London, and has worked at the Oxford Vaccine Group (University of Oxford) since 2003, conducting research related to vaccines against meningococcus, pneumococcus, Ebola virus, respiratory syncytial virus, group B streptococcus, influenza and hepatitis B disease. These include extensive involvement with clinical trials of the capsular group B meningococcal vaccine introduced into the UK routine infant immunisation schedule in September 2015.
Dr Snape has received awards for his work as a Principal Investigator from the NIHR Clinical Research Network and for public engagement with research from the Vice-Chancellor of the University of Oxford.
Dr Snape continues to work as a general paediatrician at the Children’s Hospital, Oxford and is an academic training programme director for the Oxford University Clinical Academic Graduate School. He receives salary support from the NIHR Oxford Biomedical Research Centre.
After having obtained a PhD at Leicester University, Dr Hays moved to MAFF in York and then to CPHL in Colindale, London. Approximately 16 years ago he moved to the Netherlands and has now attained the position of Associate Professor.
His research involves the development of 'bench-to-bedside' solutions in the fight against the global endemic of antimicrobial resistance and to date, he has been / is involved in 9 EU-funded projects (3 as coordinator). These projects are fairly diverse, involving the development and evaluation of new antibiotics, new antibiotic treatment strategies, new biomarkers of infection (including the human microbiota) and new (Point-of-Care) diagnostics.
Dr Richard Peabody is a medical epidemiologist, currently acting head of the Respiratory Diseases Department in Public Health England. He leads the flu and other respiratory virus surveillance team, which is responsible (amongst other things) for monitoring the national flu vaccine programme – including the new children’s flu programme.
Richard initially worked in clinical medicine and infectious diseases, before entering the EPIET programme - a two year training programme in field epidemiology - being based in Helsinki, Finland. Following completion of his UK training in public health, he worked at the WHO Regional Office for Europe and now at the National Surveillance centre on various aspects of vaccine preventable diseases and respiratory disease, including in particular influenza.
Dr E. David G. McIntosh AM is an Australian paediatrician, vaccinologist and infectious disease specialist. He is an Honorary Clinical Senior Lecturer at Imperial College, London.
His areas of research have included early-onset Group B streptococcal infection, chronic suppurative otitis media, hepatitis B virus, gene therapy for hepatitis, congenital rubella syndrome, pneumococcal conjugate vaccines, the intra-nasal cold-adapted influenza vaccine, the antibiotics tigecycline and piperacillin-tazobactam, and the anti-parasitic agent moxidectin, for the treatment of River Blindness (onchocerciasis) in Africa.
He is an Honorary Professor at the Scientific Center for Children’s Health, Moscow, Russia. David joined Takeda Vaccines in September 2015.
He holds the following qualifications: MBBS, MPH, LLM, PhD, FAFPHM, FRACP, FRCP&CH, FFPM, DRCOG, DCH, Dip Pharm Med.
Dr Michael Edelstein is a consultant epidemiologist at Public Health England’s department for Immunisation, Hepatitis and Blood safety and a research fellow at the Centre on Global Health Security at Chatham house. At Public Health England, he is the national lead for vaccine coverage data and his portfolio includes hepatitis A and the implementation of the HPV vaccine pilot for MSM.
Dr Tim Brooks CBE is Head of the Rare and Imported Pathogens Laboratory (RIPL) at Public Health England, based at Porton Down in the UK. RIPL is a WHO collaborating laboratory for High Consequence Pathogens, and provides diagnostic and clinical advice for a wide range of unusual bacterial and viral pathogens. Tim Brooks is one of the leading partners in the national Imported Fever Service, which combines the clinical skills of the Liverpool and London Tropical Infectious Disease Hospitals with RIPL laboratory services. The IFS offer a 24 hour service for acutely ill travellers arriving in the UK from anywhere in the world. His research interests range from environmental detection of microorganisms and clinical diagnostics, through aerobiology and decontamination, to disease pathogenesis and work for the European Space Agency. He led the PHE Ebola laboratories in Sierra Leone during the 2015 outbreak, and latterly in the surveillance phase in 2016.
Professor Keith Klugman is the Director of Pneumonia at the Bill and Melinda Gates Foundation in Seattle WA. He is the Emeritus William H. Foege Chair of Global Health at the Hubert Department of Global Health, Emory University, Atlanta, Georgia. In addition, he serves as an Honorary Professor in the Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, in Johannesburg, South Africa.
Professor Klugman is the Past - President of the International Society of Infectious Diseases; and a past Chair of the International Board of the American Society for Microbiology. In 2015 Keith was elected to membership of the US National Academy of Medicine. He has chaired or served on numerous expert committees for the World Health Organization (WHO), the Wellcome Trust and the Centers for Disease Control and Prevention (CDC). He serves as an editor or member of the editorial board of 16 journals.
Professor Klugman has made his major contributions in the field of pneumococcal research, including antimicrobial resistance. His work demonstrating pneumococcal conjugate vaccine efficacy in the developing world, has led to interventions that have saved millions of lives especially in Africa. He has published more than 500 scientific papers which have been cited more than 30,000 times to date. His current position allows him the opportunity to contribute to the mission of the Gates Foundation to reduce deaths from pneumonia, neonatal sepsis and meningitis in children, thus allowing them the chance to lead healthy and productive lives.
Completed his B.Sc degree in Microbiology at University College Galway before going on to study the genetics of measles virus at Queen's University of Belfast, gaining his Ph.D in 1989.
In 1994, he shifted into molecular diagnostics taking up a Clinical Scientist post at the Belfast City Hospital, focusing on immunogenetics of transplantation and host susceptibilty to disease. In 2002, he moved to Addenbrooke's Hospital, Cambridge to take up the post of "Head of Molecular Diagnostics" in the Microbiology Laboratory, which is now part of Public Health England where he remains to-date.
Andrew J Pollard, FRCPCH PhD FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford (since 2001).
His research includes the design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid. He runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal and leads a project on burden and transmission of typhoid and co-leads typhoid vaccine impact studies at these sites. He has supervised 23 PhD students and his publications include over 300 manuscripts and books on various topics in paediatrics and infectious diseases. He chairs the UK Department of Health’s Joint Committee on Vaccination and Immunisation and the European Medicines Agency scientific advisory group on vaccines and is a member of WHO’s SAGE. He received the Bill Marshall award of the European Society for Paediatric Infectious Disease (ESPID) in 2013 and the ESPID Distinguished Award for Education & Communication in 2015. He was elected to the Academy of Medical Sciences in 2016.
Professor Watson trained as a clinician (respiratory medicine) and a public health physician (infectious disease epidemiology) before becoming head of the respiratory diseases department of the Health Protection Agency, subsequently Public Health England.
He moved to the Department of Health to become Deputy Chief Medical Officer in 2013 with responsibility for health protection.
His main areas of work are the national immunisation programme, antimicrobial resistance and emergency preparedness and response.
He continues teaching and research collaborations with University College London and the London School of Hygiene and Tropical Medicine.